Alan Horsager, Ph.D.
Co-Founder and CSO

Alan Horsager has spent the last 7 years developing molecular and microelectronic prosthetic therapies for treating blindness in human patients. In addition to CSO at Eos, he holds a faculty appointment in the Department of Ophthalmology at the University of Southern California. Alan has 10 years of device and biotechnology industry experience, spanning noninvasive and implantable devices (his PhD work was in close collaboration with Second Sight Medical Products, Inc., the developer of a retinal prosthesis), pharmaceutical clinical research, regulatory affairs, and clinical project management. His academic expertise includes the study of human visual perception, computational modeling of neural systems, animal behavior, retinal physiology, and molecular biology. Alan’s combined understanding of vision neuroscience, commercialization, and industry-university collaborations serves as an excellent base to lead the scientific projects at Eos. He received his BA in Psychology from the University of Washington and his PhD in Neuroscience at the University of Southern California.

Benjamin C. Matteo
Co-Founder and CEO

Ben Matteo is an entrepreneur with experience in the biopharma, cleantech, and software industries.  Ben served as a consultant for McKinsey and Company in San Francisco, Seoul, and Tel Aviv, and worked as an independent consultant for seven years in business and technical capacities for clients ranging from startups to Fortune 500 companies. He is a Co-Founder and Member of the Board of Directors of the Cleantech Open, an international nonprofit that assists and educates entrepreneurs in the cleantech industry and builds networks across academic, government, financial, and business sectors.  Ben serves on the Board of Directors of Nila.tv, a manufacturer of high-performance LED lighting systems.  He holds an SB in Mechanical Engineering from MIT, Phi Beta Kappa, and MS in Manufacturing Systems Engineering from Stanford University, concentration in smart product design.

Ed Boyden, Ph.D.
Co-Founder

Ed Boyden is the Benesse Career Development Professor at the MIT Media Lab, assistant professor of Biological Engineering and Brain and Cognitive Sciences at MIT, and leader of the Synthetic Neurobiology Group. His group aims to discover principles for controlling neural circuits in order to understand how cognition and emotion arise, and also to enable systematic repair of intractable brain disorders such as epilepsy, Parkinson's disease, post-traumatic stress disorder, and chronic pain. In order to accomplish this, his group invents new tools for controlling and observing the computations performed by brain circuits. He has launched an award-winning series of classes at MIT that teach principles of neuroengineering from the basics of controlling and observing neural functions to starting new companies in this nascent field.  Ed's accolades include "Top 35 Innovators Under the Age of 35" by Technology Review, the NIH Director's New Innovator Award, and the Society for Neuroscience Research Award for Innovation in Neuroscience.  Ed has contributed to over 150 papers, patents, and articles, has given over 60 invited talks, and writes a column for Technology Review magazine.  He received his PhD in neurosciences from Stanford University as a Hertz Fellow, where he discovered that the molecular mechanisms used to store a memory are determined by the content to be learned.  Ed received three degrees in electrical engineering and physics from MIT.

Jennifer Lockridge, Ph.D
Development

Jennifer Lockridge is a pharmacologist who has spent the last fourteen years providing direction and support for preclinical and clinical development programs. She worked at Sirna Therapeutics (formerly Ribozyme Therapeutics, Inc.) for over 10 years and worked on multiple INDs including one for age-related macular degeneration. During her tenure at Sirna, Jennifer was responsible for many areas of development which included pharmacokinetic analysis, toxicology study oversight, project management, and regulatory filings. She was also the development team leader for a compound targeting hepatitis C which was evaluated in a Phase II clinical trial. After leaving Sirna, Jennifer started Lockridge Pharmaceutical Consulting, LLC and has continued to provide guidance to a variety of clients including biotechnology firms, large pharma and venture capital.  She received a BS in Biology from the University of Portland, a Ph.D. from the Oregon Health Sciences University, and did postdoctoral work at the FDA’s National Center for Toxicological Research.

Mehdi Doroudchi, D.V.M., Ph.D.
Head of Cell Biology

Dr. Doroudchi has more than 20 years of academic and biotechnology research and development experience in positions encompassing preclinical neurobiology research and product and technology development. He received his DVM from Shiraz University and his Ph.D. from McGill University and subsequently held postdoctoral positions at the center for research in Neuroscience and at the Montreal Neurological Institute. Mehdi has extensive background in neurodegeneration, in vivo and in vitro neurobiology methods, manipulation of neurons in tissue culture and development of models of neurodegenerative disorders. Prior to joining Eos, he has served multiple positions as senior scientist and group leader for several biotechnology companies in the areas of gene and stem cell therapy for the treatment of neurodegenerative disorders which resulted in successful IND filing. His research has also resulted in a number of publications in highly ranked and peer-reviewed journals including Journal of Cell Biology and Journal of Neuroscience.